Antimony Trisulfide Bay Leaf Frangula Alnus Bark J

證據等級: L5

預測適應症: 0 個

Antimony Trisulfide / Bay Leaf / Wormwood Complex: No TxGNN Repurposing Prediction Available

One-Sentence Summary

This submission describes a multi-component preparation combining eight herbal and mineral ingredients: Antimony Trisulfide, Bay Leaf, Frangula Alnus Bark, Jateorhiza Calumba Root, Marsdenia Condurango Bark, Menyanthes Trifoliata, Silver, and Wormwood. Because no DrugBank ID could be assigned to the combination and no original approved indication was provided, the TxGNN model was unable to generate any repurposing prediction. No evidence level can be assigned, and a full evaluation cannot proceed without foundational data.

Quick Overview

Item	Content
Original Indication	Not available
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	N/A
Taiwan Market Status	✗ Not marketed
Number of NDAs	0
Recommended Decision	Hold

Background Notes on Components

Although no TxGNN prediction was generated, the eight ingredients belong to recognisable pharmacological and ethnobotanical categories:

Ingredient	Traditional Category	Historical Use
Antimony Trisulfide	Inorganic mineral	Historical expectorant; largely obsolete
Bay Leaf (Laurus nobilis)	Botanical	Digestive, mild anti-inflammatory
Frangula Alnus Bark	Botanical (anthraquinone laxative)	Constipation; related to senna/cascara
Jateorhiza Calumba Root	Botanical (bitter)	Appetite stimulation, digestive tonic
Marsdenia Condurango Bark	Botanical	Gastric complaints; historically claimed for stomach tumours (19th century)
Menyanthes Trifoliata	Botanical	Digestive bitter, appetite stimulant
Silver	Inorganic mineral	Historical topical antimicrobial
Wormwood (Artemisia absinthium)	Botanical	Digestive tonic, traditional antiparasitic

As a group, this formulation resembles a classical European compound digestive bitter or stomach tonic, likely of 19th-century pharmacopoeial origin. The combination lacks a recognised INN, a unified DrugBank entry, and modern regulatory approval — all of which are prerequisites for TxGNN mapping.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN requires a DrugBank-mapped compound with a defined mechanism of action as its entry point. Because this submission is a multi-component mixture without a DrugBank ID or documented original indication, neither the knowledge-graph nor the deep-learning prediction pipeline could be executed. There is currently no repurposing signal to evaluate.

To proceed, the following is needed:

Decompose the combination — run each of the eight ingredients individually through TxGNN using their respective DrugBank IDs (e.g., Frangula/Cascara: DB13179; Artemisinin-class compounds for Wormwood), then assess whether any single-ingredient signal is clinically actionable
Identify the registered product — determine whether this mixture corresponds to a named historical or homeopathic product (e.g., a specific brand or pharmacopoeial formula); if so, retrieve its original approved indication from TFDA archives or historical registrations
Obtain or reconstruct the package insert — TFDA 仿單 should provide warnings, contraindications, and dosing guidance even for traditional preparations
Clarify the regulatory pathway — confirm whether any of the components are individually licensed in Taiwan or internationally, which may open an alternative evidence-collection route
Flag safety concerns proactively — Antimony Trisulfide and Silver are both potentially toxic at systemic doses; a safety review should precede any repurposing hypothesis, even at the research stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.